Omeros Corporation
Clinical trials sponsored by Omeros Corporation, explained in plain language.
-
Experimental drug targets protein leak in kidney patients
Disease control TerminatedThis study tested a drug called OMS721 (narsoplimab) in 31 people with certain kidney diseases, including IgA nephropathy and lupus nephritis. The main goal was to check safety and see if it reduces protein in the urine, a sign of kidney damage. The study was stopped early, so re…
Phase: PHASE2 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated May 26, 2026 10:46 UTC
-
Experimental drug targets rare blood disorder in phase 3 trial
Disease control TerminatedThis study tested a drug called narsoplimab (OMS721) in adults and teenagers with atypical hemolytic uremic syndrome (aHUS), a rare condition that causes blood clots and organ damage. The main goal was to see if the drug could improve platelet counts and was safe. The trial was s…
Phase: PHASE3 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated May 26, 2026 10:35 UTC
-
Kidney disease drug trial halted midway
Disease control TerminatedThis study tested a drug called OMS721 in 360 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal was to see if the drug could lower protein levels in urine, a sign of kidney damage. The trial was stopped early, so results are limited.
Phase: PHASE3 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated May 18, 2026 12:07 UTC